Parkinson's disease
Conditions
Interventions
None listed
Sponsors
Tridem Bioscience FlexCo
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Outcome results
None listed
An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Jul 23, 2026